Objective To observe the clinical effect of Zhidai decoction combined with recombinant human interferon in treatment of chronic cervicitis combined with high-risk HPV infection.
Methods Total 338 cases of chronic cervicitis with high risk HPV infection were enrolled into this study and were divided into control group (
n=169) and observation group (
n=169) by the random number table. The patients in the control group were administrated with recombinant human interferon α2b suppository, while the patients in the observation group were treated with Zhidai decoction combined with recombinant interferon α2b suppository. The adverse drug reactions during the treatment were recorded. The improvement of leucorrhea and the changes of positive rate of high risk HPV were observed. The curative effect and the recurrence of cervicitis were statistically compared.
Results There was no statistically significant in the incidence of adverse drug reactions between the observation group (5.32%) and the control group (3.55%),
P<0.05. The levels of serum TNF-α, IL-6 and IL-8 in the observation group were significantly lower than those in the control group (
P<0.05). The improvement rate of leucorrhea quantity, leucorrhea purulent and positive high risk type HPV (96.45%, 97.04% and 92.90%) were significantly higher than those in the control group (85.21%, 86.39% and 80.47%) at the end of treatment (
P<0.05). The total effective rate of cervicitis in the observation group (95.27%) was significantly higher than that in the control group (82.25%),
P<0.05. The recurrence rate on the 6th and 12th month after the treatment in the observation group (3.55% and 8.88%) was significantly lower than that of the control group (10.06% and 19.53%),
P<0.05.
Conclusion Compared with recombinant interferon therapy alone, Zhidai decoction combined with recombinant human interferon, with a high safety, can more effectively improve the clinical symptoms and curative effect of chronic cervicitis patients with high-risk HPV infection, decrease the positive of high risk type HPV infection, and prevent the recurrence of cervicitis.